CA Patent

CA2971349C — Potent compstatin analogs

Assigned to University of Pennsylvania Penn · Expires 2020-09-08 · 6y expired

What this patent protects

Compounds comprising peptides and peptidomimetics capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds.

USPTO Abstract

Compounds comprising peptides and peptidomimetics capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds.

Drugs covered by this patent

Patent Metadata

Patent number: CA2971349C
Jurisdiction: CA
Classification: —
Expires: 2020-09-08
Drug substance claim: No
Drug product claim: No
Assignee: University of Pennsylvania Penn
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.